Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid in relapsed or refractory Waldenstrom Macroglobulinemia
NCT02302469Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Mar 2009
- Primary completion
- Mar 2017
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide in Waldenstrom macroglobulinemia (WM), sponsored by CHU de Lille. Primary endpoint: Dose Limiting Toxicities at 1 month. Started Mar 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02302469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02302469.